Skip to content

BioCryst 制药

US · BCRX #2766 按市值排名 上市于 1970
7.79 -0.23 -2.87%
实时 - 追踪5344个代码 - 心跳于313秒前 · 2026-10-16 19:30

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了3家。
  • 机构持股总比例下降了0.5个百分点。

机构持股

机构持股比例
103.79% -0.47pp
机构数量
376 -3
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund54.54%
Hedge Fund22.21%
VC/PE Fund17.01%
Public Company4.30%
Private Company3.61%
Government Pension Fund1.15%
Individual/Insider0.90%
Insurance Company0.75%
Family Office/Trust0.16%

主要股东 截至 2026-06-30

BlackRock 9.35% · 23.89M 股
RA Capital Management, L.P. 6.19% · 15.83M 股
State Street Global Advisors 5.94% · 15.19M 股
Deerfield Management Company, L.P. 5.91% · 15.10M 股
Vanguard Capital Management, LLC 5.14% · 13.12M 股
Vanguard Portfolio Management, LLC 4.36% · 11.14M 股
TCG Crossover Management, LLC 4.31% · 11.02M 股
Perceptive Advisors LLC 4.03% · 10.31M 股
Janus Henderson Group plc 3.73% · 9.54M 股
Vestal Point Capital, LP 3.25% · 8.30M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 38次买入 · 9次卖出

姓名职务持股比例
Jon Stonehouse Chief Executive Officer 0.41%
Charles Gayer Chief Commercial Officer 0.14%
Anthony Doyle Senior Vice President 0.08%
Helen Thackray Chief Research & Development Officer 0.06%
Alane Barnes Chief Legal Officer 0.06%
Vincent Milano Independent Director 0.04%
Steven K. Galson Independent Director 0.02%
Theresa Heggie Independent Director 0.02%
Alan Levin Independent Director 0.02%
Ronald Dullinger Chief Commercial Officer 0.02%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-08-30 Vincent Milano Independent Director Other Acquisition +1,159 $9.70
2026-08-30 Steve Frank Director Other Acquisition +1,288 $9.70
2026-08-30 Jill Milne Director Other Acquisition +1,288 $9.70
2026-08-30 Jon Stonehouse Chief Executive Officer Other Acquisition +644 $9.70
2026-08-30 Amy McKee Independent Director Other Acquisition +644 $9.70
2026-06-10 Vincent Milano Independent Director Other Acquisition +15,294 --
2026-06-10 Vincent Milano Independent Director Other Derivative Acquisition +33,540 $8.50
2026-06-10 Alan Levin Independent Director Other Acquisition +15,294 --
2026-06-10 Alan Levin Independent Director Other Derivative Acquisition +33,540 $8.50
2026-06-10 Steve Frank Director Other Acquisition +15,294 --
2026-06-10 Steve Frank Director Other Derivative Acquisition +33,540 $8.50
2026-06-10 Jill Milne Director Other Acquisition +15,294 --
2026-06-10 Jill Milne Director Other Derivative Acquisition +33,540 $8.50
2026-06-10 Theresa Heggie Independent Director Other Acquisition +15,294 --
2026-06-10 Theresa Heggie Independent Director Other Derivative Acquisition +33,540 $8.50
2026-06-10 Jon Stonehouse Chief Executive Officer Other Acquisition +15,294 --
2026-06-10 Jon Stonehouse Chief Executive Officer Other Derivative Acquisition +33,540 $8.50
2026-06-10 Steven K. Galson Independent Director Other Acquisition +15,294 --
2026-06-10 Steven K. Galson Independent Director Other Derivative Acquisition +33,540 $8.50
2026-06-10 A. Sanders Independent Director Other Acquisition +15,294 --

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

BioCryst 制药 讨论区 0 条评论

发表评论